How JIDEYTRO was studied
JIDEYTRO was studied in advanced ROS1+ NSCLC
A clinical study was run to determine 3 key results:
The number of people whose cancer responded*
How long the treatment continued to work
What side effects people experienced
*This was the primary goal of the clinical study.
The study looked at how JIDEYTRO may help people after various treatment experiences in ROS1+ NSCLC
The clinical benefit of JIDEYTRO was studied in 117 people who were already treated with 1 to 4 ROS1-targeted therapies for advanced ROS1+ NSCLC.
There was a wide range in the number of prior therapies people had received and in which therapies they had received
50%
of people had received 1 prior ROS1-targeted therapy before JIDEYTRO
50%
of people were heavily pretreated with 2 or more ROS1-targeted therapies before JIDEYTRO
Previous ROS1-targeted therapies included: crizotinib, entrectinib, lorlatinib, repotrectinib, and/or taletrectinib.
52% (61 out of 117) had also received prior chemotherapy.
The study included people with two known treatment challenges in ROS1+ NSCLC:
See the results for people who received JIDEYTRO in the clinical study.
How to take JIDEYTRO
Learn about taking once-daily JIDEYTRO, a medication that can coexist with your routine.
Download JIDEYTRO resources
Explore educational resources as you
consider next steps.
NSCLC=non-small cell lung cancer; ROS1+=ROS proto-oncogene 1-positive.